Tag Archives: Myriad

Mayo Meet Alice Meet Myriad – Fed. Cir. Appreciates “Abstract Art”

Posted on December 18, 2014 by Warren Woessner

On December 20th, a panel of the Fed. Cir. of Judges Dyk, Clevinger and Prost – Dyk writing – found that six claims in Myriad’s dwindling arsenal of BRACA1 and 2 patents were invalid as claiming non-statutory subject matter. (University … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , | 2 Comments

Genetic Technologies v. Bristol Myers – 101 At Work

Posted on November 5, 2014 by Warren Woessner

In the recent memorandum opinion, the court invalidated claim 1 of U.S. Pat. No. 5,612,179, owned by Genetic Technologies, Ltd., as “impermissibly [claiming] a natural phenomenon.” (Genetic Technologies, Ltd. v. Bristol-Myers Squibb Company, C.A. No. 12-394-LPS (D. Delaware, Oct. 30, … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | 1 Comment

Australia: Cancer Voices v Myriad Opinion Affirmed

Posted on September 5, 2014 by Warren Woessner

This is a guest post from Paul Cole. An opinion was handed down earlier today by the Federal Court of Australia – Full Court (Allsop C.J., Downsett, Kenny, Bennett and Middleton J.J., D’Arcy v Myriad Genetics Inc [2014] FCAFC 115 … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , , , , | 2 Comments

101 Rejections Under the Guidelines: Mayo and Myriad “Go Viral”

Posted on September 4, 2014 by Warren Woessner

This is a guest post from Hans Sauer, Deputy General Counsel, Intellectual Property for BIO. “Recently, I set out to find real-world examples of recent rejections under the USPTO Guidance, to do my own sampling rather than rely on reported … Continue reading →

Posted in Claim Interpretation | Tagged , , , , , , , , , , , , | 1 Comment